Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

ficacy assessments for each participant were based on the American College of Rheumatology criteria, which denotes at least a 20% (ACR 20) improvement, at least a 50% (ACR 50) improvement, or at least a 70% (ACR 70) improvement, from the baseline assessment at the end of the 3 month treatment period. The ACR measurement factors included reported physician and patient global assessment of disease activity, patient reported pain score, and any change in CRP in the patient's blood. The primary efficacy endpoint for the clinical trial was the percent of patients assigned to the R788 100 mg bid dose who were ACR 20 responders at the end of 3 months. Secondary efficacy endpoints included other ACR scores and, a comparison of response rates for the R788 100 mg bid dose versus placebo as determined by MRI using the modified RAMRIS scoring system of wrists and hands at baseline and at month 3.

R788 and RA

RA is a progressive, painful and potentially debilitating disease, that affects more than 2 million people in the U.S. It is a chronic inflammatory disease that puts the body's immune system into overdrive where it ultimately causes inflammation in the joints and destroys soft tissues, cartilage and bone. Rigel's R788 is a novel, orally available syk kinase inhibitor designed to interrupt the cellular signaling at the trigger point of inflammation, thereby stopping the progression of the disease. In July 2009, Rigel announced results from its Phase 2b TASKi2 clinical trial showing significant improvement in RA patients treated with R788 who had failed to respond to methotrexate treatment.

Conference Call and Webcast Information

Rigel will host a conference call to discuss the R788 TASKi3 Phase 2b clinical trial of R788 in rheumatoid arthritis, the Company's plans for further development and related matters today, July 23, 2009, at 7:00 pm EDT/ 4:00 pm PDT. A presentation related to the TASKi3
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the ... Estimates and Forecasts, 2012-2018"  report to their offering. ... by 2016. The North America ... while Europe claims approximately 25% ...
(Date:12/15/2014)... MEETING, Pa. , Dec. 15, 2014 /PRNewswire/ ... announced today it has been added to the ... NASDAQ Biotechnology Index will become effective upon market ... NASDAQ Biotechnology Index is designed to track the ... are classified as either biotechnology or pharmaceutical according ...
(Date:12/15/2014)... , December 15, 2014 Investor-Edge has ... ZGNX ), Eli Lilly and Company (NYSE: ... (NYSE: SNY ), and Novartis AG (NYSE: ... be accessed at: http://investor-edge.com/register . On Friday, ... 1.16%, the Dow Jones Industrial Average lost 1.79%, to finish ...
Breaking Medicine Technology:Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5
... Oct. 28 Octapharma Group and Fresenius Kabi ... regarding the use of Fresenius Kabi,s HESylation® Technology ... the agreement, Fresenius Kabi will license its proprietary ... based on hydroxyethyl starch ("HES") which will be ...
... , MALVERN, Pa., Oct. 28 Featuring the lowest ... Siemens Healthcare,s SOMATOM® Definition Flash dual-source computed tomography (CT) ... for Children, Orlando, Fla., to better serve its pediatric ... of the radiation dose that systems previously required to ...
Cached Medicine Technology:Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 2Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 3Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children 2Siemens Delivers Flash Speed, Lowest Dose to Arnold Palmer Hospital for Children 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... FRANCISCO, Sept. 18 DuPont Group Vice,President Mark ... of America,Securities 37th Annual Investor Conference today that ... meeting growing global demands,for products and services that ... "DuPont is uniquely positioned to deliver innovations for ...
... efficiently and inexpensively producing novel pharmaceutical compounds, such ... as well as high-value chemicals, as the result ... researchers. , In work that could transform radically ... are produced commercially, the UB researchers are genetically ...
... study finds , , TUESDAY, Sept. 18 (HealthDay News) -- ... by looking at Web sites can leave would-be patients ... study finds. , In looking over six hospital-comparison Web ... inappropriate or incomplete standards to measure a center,s quality, ...
... As predicted by opponents,to "assisted suicide," those seeking to ... slope,. Supporters of "assisted suicide,",including a few members of ... free counseling sessions -- via a new 1-800 number ... own lives. "This effort to put a clerical ...
... Mich., Sept. 18 Oakwood Southshore,Medical Center (OSMC) ... thanks to a generous gift from Anthony J. ... downriver hospital., "The Southshore Promise is really ... division president, Oakwood Southshore,Medical Center. "We are in ...
... ... Survey, SEATTLE, Sept. ... today to,draw attention to an imminent access to care problem for Washington,s ... January 1, 2008, and physicians are deeply concerned about,the cut,s impact on ...
Cached Medicine News:Health News:DuPont Focused on Meeting Global Demands for Greater Safety & Protection 2Health News:Researchers genetically engineer micro-organisms into tiny factories 2Health News:Researchers genetically engineer micro-organisms into tiny factories 3Health News:Hospital Quality Info on Web Can Be Misleading 2Health News:Hospital Quality Info on Web Can Be Misleading 3Health News:$1 Million Gift Boosts Downriver Community 2Health News:Medicare Cuts to Physicians Will Harm Washington Seniors 2
PremierEdge™ Implant Knives....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: